NR1H4 and metabolic dysfunction-associated steatohepatitis: FXR agonists targeting the gut-liver axis are promising for NAFLD/NASH for they not only relieve hepatic steatosis but also resolve fibrosis at histology level by antagonizing NFκB [285, 286].